Company Profile
AstraZeneca PLC Stock Price, News & Catalysts
- Ticker:
- AZN
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs, Biologics
- Location:
- UK
Stock performance
158.61 USD (+1.33%)
Close
Last updated: October 6, 2026
275B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, AZN closed up 1.33% at $158.61. No new same-company headline was identified in the current news window.
Company overview
Global Science-Led Biopharmaceutical Company
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across oncology, biopharmaceuticals, and rare disease. Its BioPharmaceuticals business includes cardiovascular, renal and metabolic disease, respiratory and immunology, and infectious disease, while Alexion forms the core of the rare-disease organization.
Oncology Portfolio
Oncology is AstraZeneca's largest therapeutic area and includes established medicines such as Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Datroway, Truqap, and Etcamah. The pipeline combines targeted therapies, antibody-drug conjugates, immuno-oncology, bispecific antibodies, radioconjugates, and cell therapies across lung, breast, gastrointestinal, genitourinary, gynecologic, and hematologic cancers.
Cardiovascular, Renal and Metabolic Disease
The CVRM portfolio is built around Farxiga and other medicines addressing heart failure, chronic kidney disease, diabetes, and cardiovascular risk. Late-stage programs include Baxfendy for hypertension and primary aldosteronism, balcinrenone combinations in heart failure, zibotentan combinations in kidney disease, oral PCSK9 inhibitor laroprovstat, and oral GLP-1 candidate elecoglipron.
Respiratory, Immunology and Infectious Disease
AstraZeneca markets respiratory and immune medicines including Fasenra, Tezspire, Breztri, and Saphnelo. Its pipeline targets asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, lupus, systemic sclerosis, cutaneous lupus, and other inflammatory conditions, with programs using antibodies, inhaled biologics, and combination approaches.
Rare Disease Through Alexion
The rare-disease portfolio includes complement inhibitors Ultomiris and Soliris, metabolic and enzyme-replacement therapies, and medicines for neuromuscular and hematologic disorders. Development programs include gefurulimab in generalized myasthenia gravis, anselamimab in AL amyloidosis, efzimfotase alfa in hypophosphatasia, and additional complement and protein-depletion approaches.
Broad Technology and Development Platform
AstraZeneca's pipeline spans small molecules, monoclonal and bispecific antibodies, antibody-drug conjugates, oligonucleotides, radioconjugates, and cell therapies. As of its first-half 2026 update, the company reported 183 pipeline projects, including 116 Phase 2 or Phase 3 new molecular entities or major life-cycle programs and 21 late-stage new molecular entities.
Future catalysts
- Regulatory decisions in the second half of 2026 for Datroway in first-line metastatic triple-negative breast cancer for patients who are not candidates for immunotherapy in the European Union, Japan, and China.
- Japan regulatory decision in the second half of 2026 for Imfinzi in high-risk non-muscle-invasive bladder cancer based on the POTOMAC program.
- European Union regulatory decision in the second half of 2026 for Truqap in PTEN-deficient metastatic hormone-sensitive prostate cancer.
- U.S. regulatory decision in the second half of 2026 for Etcamah in ESR1-mutated, HR-positive/HER2-negative advanced breast cancer using a first-line switch strategy.
- Phase 3 data readouts in the second half of 2026 from AVANZAR, TROPION-Lung15, SERENA-4, PACIFIC-9, SAFFRON, and CROSSING.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AstraZeneca PLC (AZN)?
AstraZeneca PLC (AZN) most recently closed at 158.61 USD, a +1.33% move versus the previous session.
What is the market cap of AstraZeneca PLC (AZN)?
AstraZeneca PLC currently has a market capitalization of 275B USD on BioPharmSignal.
What does AstraZeneca PLC do?
Global Science-Led Biopharmaceutical Company AstraZeneca is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across oncology, biopharmaceuticals, and rare disease. Its BioPharmaceuticals business includes cardiovascular, renal and metabolic disease, respiratory and immunology, and infectious...
On which exchange is AZN stock listed?
AstraZeneca PLC (AZN) is associated with NASDAQ, UK, Small Molecule Drugs, Biologics.
What is GLP-1?
Late-stage programs include Baxfendy for hypertension and primary aldosteronism, balcinrenone combinations in heart failure, zibotentan combinations in kidney disease, oral PCSK9 inhibitor laroprovstat, and oral GLP-1 candidate elecoglipron.
Which conditions is AstraZeneca PLC targeting with GLP-1?
AstraZeneca PLC is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does AstraZeneca PLC describe recent progress with GLP-1?
Regulatory decisions in the second half of 2026 for Datroway in first-line metastatic triple-negative breast cancer for patients who are not candidates for immunotherapy in the European Union, Japan, and China. Japan regulatory decision in the second half of 2026 for Imfinzi in high-risk non-muscle-invasive bladder cancer based on the POTOMAC program....
What is SERENA-4?
Phase 3 data readouts in the second half of 2026 from AVANZAR, TROPION-Lung15, SERENA-4, PACIFIC-9, SAFFRON, and CROSSING.